Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery

Therapeutic Delivery

Volumn 1, Issue 1, 2010, Pages 63-73

  Rawat, Manoj K ^a   Jain, Achint ^a   Mishra, Amit ^a   Muthu, Madaswamy S ^b   Singh, Sanjay ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIACYLGLYCEROL; FATTY ACID; GLYCEROL BEHENATE; GLYCEROL STEARATE; MONOACYLGLYCEROL; POLOXAMER; REPAGLINIDE; SOLID LIPID NANOPARTICLE; STEARIC ACID; TRIACYLGLYCEROL; TRISTEARIN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG STORAGE; ELECTRON DIFFRACTION; HUMIDITY; IN VITRO STUDY; PARTICLE SIZE; PRIORITY JOURNAL; SOLID STATE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 79955039553     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.7     Document Type: Article

References (43)

1. Muller RH, Maaben S, Weyhers H. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int. J. Pharm. 138, 85-94 (1996). (Pubitemid 26241925)
2. Hussain N, Jaitley V, Florence AT. Recent advances in the understanding of uptake of microparticulate across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50(1-2), 107-142 (2001). (Pubitemid 32727279)
3. Wasan KM. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. Drug Dev. Ind. Pharm. 27(4), 267-276 (2001). (Pubitemid 32531593)
4. Holm R, Mullertz A, Christensen E, Hoy CE. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rat. Eur. J. Pharm. Sci. 14(4), 331-337 (2001). (Pubitemid 33001626)
5. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J. Control. Release 95, 627-638 (2004). (Pubitemid 38344153)
6. Muller RH, Runge S, Ravelli V. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317(1), 82-89 (2006). (Pubitemid 43866342)
7. Li H, Zhao X, Ma Y. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J. Control. Release 133, 238-244 (2009).
8. Yang S, Zhu J, Lu Y. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 16, 751-757 (1999). (Pubitemid 29227107)
9. Zara GP, Bargoni A, Cavelli R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J. Pharm. Sci. 91, 1324-1333 (2000). (Pubitemid 34651194)
10. Mayer-Davis EJ, Levin S, Bergman RN. Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Metab. Res. 17, 137-145 (2001). (Pubitemid 32427962)
11. Jain SK, Agrawal GP, Jain NK. A novel calcium silicate based microspheres of repaglinide: in vivo investigations. J. Control. Release 113, 111-116 (2006). (Pubitemid 43928144)
12. Skaug V, Davies V, Gylseth RB. In vitro macrophage cytotoxicity of five calcium silicates. Br. J. Ind. Med. 41, 116-121 (1984). (Pubitemid 14093267)
13. Eldridge JH, Hammond CJ, Meulbroek JA. Influence of the degrees of hydrolyzation and polymerization of poly(vinylalcohol) on the preparation and properties of poly(dl-lactide-co-glycolide) nanoparticle. J. Control. Release 11, 205-214 (1990).
14. Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications. Adv. Drug Deliv. Rev. 47, 165-196 (2001). (Pubitemid 32324113)
15. Porter CJ, Charman WN. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 50, S127-S147 (2001). (Pubitemid 32905359)
16. Remko M. Theoretical study of molecular structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some hypoglycemic agents. J. Mol. Struct. Theochem. 15, 73-82 (2008).
17. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find. Exp. Clin. Pharmacol. 27, 1-20 (2005).
18. Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int. J. Pharm. 157, 171-179 (1997). (Pubitemid 27471169)
19. Freitas X, Muller RH. Spray-drying of solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 46, 145-151 (1998).
20. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm. 257(1-2), 153-160 (2003). (Pubitemid 36507041)
21. Luo YF, Chen DW, Ren LX. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J. Control. Release 114(1), 53-59 (2006).
22. Muhlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45(2), 149-155 (1998). (Pubitemid 28167741)
23. Windbergs M, Strachan CJ, Kleinebudde P. Understanding the solid-state behaviour of triglyceride solid lipid extrudates and its influence on dissolution. Eur. J. Pharm. Biopharm. 71, 80-87 (2009).
24. Westesen K, Siekmann B. Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions. Eur J. Pharm. Biopharm. 43, 104-109 (1996). (Pubitemid 26173945)
25. Reddy H, Murthy RSR. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS PharmSciTech. 6(2), e158-e166 (2005). (Pubitemid 41631757)
26. Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles: evaluation of the method and process parameters. Eur. J. Pharm. Biopharm. 55, 125-131 (2003). (Pubitemid 36120504)
27. Singh S, Muthu MS. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine 2, 233-240 (2007). (Pubitemid 46845769)
28. Verger ML, Fluckiger L, Kim Y. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur. J. Pharm. Biopharm. 46, 137-143 (1998). (Pubitemid 28414471)
29. Muthu MS, Singh S. Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine 3, 305-319 (2008). (Pubitemid 351827308)
30. Moneghini M, Volinovich D, Princivalle F. Formulation and evaluation of vinypyrrolidone/vinylacetate copolymer microspheres with carbamazepine. Pharm. Dev. Technol. 5, 347-353 (2000). (Pubitemid 30602842)
31. Chrony M, Fishbein I, Danenberg HD. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J. Control. Release 83, 389-400 (2002). (Pubitemid 35223261)
32. Muthu MS, Singh S. Poly(d,l-lactide) nanosuspensions of risperidone for parenteral delivery: formulation and in vitro evaluation. Curr. Drug Deliv. 7, 62-68 (2009).
33. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2, 219-232 (2007). (Pubitemid 46845768)
34. Jenning V, Thunemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199, 167-177 (2000). (Pubitemid 30236188)
35. Kumar VV, Chandrasekar D, Ramakrishna S. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int. J. Pharm. 335, 167-175 (2007). (Pubitemid 46482862)
36. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177 (2000). (Pubitemid 30326695)
37. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13(2), 123-133 (2001). (Pubitemid 32288781)
38. Briger I, Duberne C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002). (Pubitemid 35247520)
39. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat. Drug Deliv. Formul. 2, 120-135 (2008).
40. Hu FQ, Jiang SP, Du YZ. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B. Biointerfaces 45, 167-173 (2005).
41. Cavalli R, Aquilano D, Carrlotti ME, Gasco MR. Study by x-ray powder diffraction and differential scanning calorimetry of two model drugs, phenothiazine and nifedipine, incorporated into lipid nanoparticles. Eur. J. Pharm. Biopharm. 41, 329-333 (1995).
42. Jenning V, Gohla SH. Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int. J. Pharm. 196, 219-222 (2000). (Pubitemid 30105747)
43. Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). Microencapsul. 18, 149-158 (2001). (Pubitemid 32177833)